logo-loader
ImmuPharma PLC

Immupharma chairman details £2.66mln financing and open label extension study

ImmuPharma PLC’s (LON:IMM) chairman Tim McCarthy caught up with Proactive London's Andrew Scott to discuss the results of a follow-up study which was designed to evaluate Lupuzor’s safety and tolerability.

McCarthy says the six month extension study confirmed its outstanding and robust safety profile.

He also details the subscription agreement with institutional investor, Lanstead Capital, which brought in around £2.66mln.

Quick facts: ImmuPharma PLC

Price: £0.10

Market: AIM
Market Cap: £15.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Analyst sees 'clear rationale' for ImmuPharma to move forward with Lupuzor

The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on ImmuPharma PLC (LON:IMM) and its flagship drug Lupuzor - a treatment for the autoimmune disease Lupus. Dr Malik says despite not meeting its primary end point in a recent phase III trial, the response rate...

on 5/6/19

2 min read